

GLX Analytix Joins Harvard's Wyss Diagnostics Accelerator to Deliver Disruptive Innovation to Hard Diagnostics Problems

GLX Analytix embraces opportunity to form partnerships that accelerate the commercialization of a game-changing platform impacting broader diagnostics ecosystem



SILICON VALLEY, CALIFORNIA, UNITED

STATES, April 13, 2023 /EINPresswire.com/ -- GLX Analytix today announced that it joined the Wyss Diagnostics Accelerator's (Wyss DxA) Industrial Participant Program (IPP). The Wyss DxA IPP is a collaboration hub between healthcare technology companies and the scientific and clinical community. This initiative reaches programs within the Wyss Institute, as well as its affiliated

"

We are thrilled to join this hub of esteemed and diverse changemakers that are laser-focused on accelerating transformative diagnostic tests to the benefit of patients and, ultimately, saving lives." Brian Della Valle, CEO, GLX Analytix institutions and a broader diagnostics ecosystem.

As the first program of its kind at Harvard's Wyss Institute, the Wyss DxA IPP was formed to create and deliver disruptive technologies to address unmet clinical needs in the screening, diagnosis, prognosis, and management of diseases.

Through its participation in the IPP, GLX Analytix will collaborate with distinguished clinicians, researchers, engineers, funding agencies, philanthropists, government agencies, and industry partners.

"We are thrilled to join this hub of esteemed and diverse changemakers that are laser-focused on accelerating transformative diagnostic tests to the benefit of patients and, ultimately, saving lives," says GLX Analytix CEO Brian Della Valle. "We are at a pivotal moment in personalized healthcare. GLX Analytix's mission to bring personalized medicine to millions of people worldwide aligns with the mission of Wyss DxA IPP."

GLX Analytix's unique approach, with possibilities for early diagnosis, prediction, and monitoring of autoimmune and neurodegenerative diseases, has the potential to improve the lives of

patients worldwide.

The Wyss DxA is co-led by Rushdy Ahmad, Ph.D., and David Walt, Ph.D. Walt is a Core Faculty member at the Wyss Institute, a Professor of Pathology at the Brigham and Women's Hospital, and a scientific co-founder of several life science companies.

"The mission of the Wyss DxA is to get transformative diagnostic tests to market and reduce disease burden for patients with major unmet needs. We aim to compress timelines and measure impact on lives. GLX Analytix was invited to join the Industrial Partnership Program and is already forming meaningful partnerships with our stakeholder network," said Dr. Ahmad.

About GLX Analytix:

At GLX Analytix, we combine a new, proprietary class of biomarkers with AI to bring personalized medicine to your healthcare. We envision a future where patients are diagnosed earlier, empowered to monitor themselves, and treatment plans are optimized. We aim to improve the lives of patients all over the world. <u>www.glxanalytix.com</u>

Winner of Roche Future of Healthcare Startup Award "...this approach has a clear potential to improve the lives of patients all over the world." - Dr. Tim M. Jaeger, Global Head of Diagnostics Information Solutions, Roche

Carolyn McCusker Beasley & McCusker Communications for GLX Analytix +1 650-291-0992 email us here Visit us on social media: LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/627626875

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2023 Newsmatics Inc. All Right Reserved.